Targeting IL-17A: A New Frontier in the Treatment of Colitis-Associated Cancer
Current Cancer Research · 2025
DOI: 10.64229/2ew2fm31 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Cancer Research, 2025. Verfasst von Ashok Kumar Pandurangan. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ulcerative colitis (UC) is characterized by chronic inflammation in the colon that can lead to the development of colitis-associated cancer if left untreated. Interleukin-17A (IL-17A), an inflammatory cytokine produced by Th17 cells, plays a crucial role in mediating inflammatory reactions in autoimmune diseases like inflammatory bowel disease and has been implicated in colitis associated cancer development. This review discusses the importance of IL-17A in colitis associated cancer pathogenesis and examines novel therapies targeting IL-17A as potential treatments. Evidence from animal studies demonstrates that inhibition of IL-17A signaling can suppress intestinal inflammation and tumor development in colitis associated cancer models. Several natural compounds like cocoa, embelin, β-carotene, and melatonin have shown promise in reducing IL-17A expression and colitis associated cancer progression in preclinical studies. Additionally, administration of IL-17A antibodies has been found to decrease tumor formation in mouse models of colitis associated cancer. Recent research has also revealed the role of microRNAs like microRNA-146a in modulating IL-17 responses and limiting tumorigenic inflammation. While further research is needed, targeting the IL-17A pathway represents a promising therapeutic approach for preventing and treating colitis associated cancer. This review summarizes the current evidence supporting IL-17A as a key mediator of colitis associated cancer and highlights potential strategies to inhibit this pathway for therapeutic benefit.
Zitieren
APA
Pandurangan, A. K. (2025). Targeting IL-17A: A New Frontier in the Treatment of Colitis-Associated Cancer. Current Cancer Research. https://doi.org/10.64229/2ew2fm31
Vancouver
Pandurangan AK. Targeting IL-17A: A New Frontier in the Treatment of Colitis-Associated Cancer. Current Cancer Research. 2025. doi:10.64229/2ew2fm31
BibTeX
@article{Pandurangan2025,
author = {Pandurangan, Ashok Kumar},
title = {Targeting IL-17A: A New Frontier in the Treatment of Colitis-Associated Cancer},
journal = {Current Cancer Research},
year = {2025},
doi = {10.64229/2ew2fm31}
}
EUVIMED